URGN – urogen pharma ltd. - ordinary shares (US:NASDAQ)
Stock Stats
News
UroGen Pharma Ltd. (NASDAQ: URGN) had its price target lowered by analysts at HC Wainwright from $64.00 to $55.00. They now have a "buy" rating on the stock.
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102 [Yahoo! Finance]
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Form 10-K UroGen Pharma Ltd. For: Dec 31
Form 8-K UroGen Pharma Ltd. For: Mar 10
Form 8-K UroGen Pharma Ltd. For: Feb 14
Form SCHEDULE 13G/A UroGen Pharma Ltd. Filed by: Adage Capital Management, L.P.
Form SCHEDULE 13G/A UroGen Pharma Ltd. Filed by: MORGAN STANLEY
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.